𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

✍ Scribed by C.-H. Hung; C.-M. Lee; S.-N. Lu; J.-H. Wang; T.-H. Hu; H.-D. Tung; C.-H. Chen; W.-J. Chen; C.-S. Changchien

Book ID
108885866
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
87 KB
Volume
13
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Varying incidence of cirrhosis and hepat
Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy
✍ Michiko Shindo; Arai Ken; Tadao Okuno πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 3 views

## BACKGROUND. To determine whether interferon (IFN) therapy can reduce incidence of the development of cirrhosis and hepatocellular carcinoma equally in patients with chronic hepatitis C virus (HCV) who responded differently to therapy, a retrospective analysis of 250 patients treated with IFN wa

Variants in interferon-alpha pathway gen
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial
✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 270 KB πŸ‘ 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may